圣诺生物：全资子公司近日收到醋酸加尼瑞克注射液的《药品注册证书》

Core Viewpoint - The announcement indicates that Chengdu Shengnuo Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Shengnuo Biotech, has received a drug registration certificate from the National Medical Products Administration for Ganirelix Injection, enhancing the company's product pipeline in the reproductive health sector [1] Group 1 - The drug registration certificate was issued for Ganirelix Injection, with the acceptance number CYHS2400298 and registration standard number YBH16462025 [1] - The specification of the drug is 0.5ml containing 0.25mg (calculated as C H ClN O) [1] - The drug is classified as a Class 4 chemical drug and is intended for domestic production [1] Group 2 - Ganirelix Injection is used in assisted reproductive technology to prevent premature luteinizing hormone surges [1] - The acquisition of the drug registration certificate will enrich the company's injectable product line and enhance its market competitiveness in the assisted reproduction field [1]